The results of the COMPLETE trial published in September 2019 showed that patients with ST segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease who underwent complete revascularisation benefitted from a lower risk for cardiovascular (CV) death or new myocardial infarction (MI) [2]. However, as Dr Pinilla-Echeverri explained during her presentation, “whether the benefit of routine non-culprit lesion percutaneous coronary intervention might be associated with vulnerable plaque morphology is unclear.”
Using OCT to image thin-cap fibroatheromas, the researchers identified vulnerable plaques in 93 patients (mean age 61 years; 83% male). Among obstructive lesions, 35.4% were identified as containing thin-cap fibroatheroma, while only 23.2% of non-obstructive lesions had thin-cap fibroatheroma (P=0.022). Although the lengths and lumen areas of obstructive versus non-obstructive thin-cap fibroatheromas were similar, significant differences were observed in the lesion lipid content and features of plaque vulnerability.
Overall, nearly half (47.3%) of patients undergoing OCT in this analysis had an obstructive non-culprit lesion with vulnerable plaque. The researchers concluded that these findings may help explain the benefit of routine percutaneous coronary intervention of obstructive non-culprit lesions in patients with STEMI and multivessel disease. Further research is required to determine the best strategy post-PCI for the STEMI patients with only non-culprit obstructive lesions and without vulnerable plaque morphology as determined by OCT.
- Pinilla-Echeverri N, et al. OCT COMPLETE: Non-culprit Lesion Plaque Morphology in Patients with ST-segment Elevation Myocardial Infarction: Substudy from the Complete Trial using Optical Coherence Tomography (OCT). LBS04, AHA Scientific Sessions 2019, 14-18 November, Philadelphia, USA.
- Mehta SR, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019 Oct 10;381(15):1411-1421.
Posted on
Previous Article
« Carvedilol does not improve exercise performance in Fontan patients Next Article
New RNAi therapies to reduce triglycerides: 2 studies show favourable results »
« Carvedilol does not improve exercise performance in Fontan patients Next Article
New RNAi therapies to reduce triglycerides: 2 studies show favourable results »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
New guidelines on the prevention of cardiovascular conditions
February 26, 2020
Balloon-expandable better than self-expanding transcatheter heart valves
February 26, 2020
Testosterone gel increases left ventricular mass
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com